The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Insulin-like Growth Factor Receptor Inhibitors: Baby or the Bathwater?
Open accessAbstract
The success of targeted therapies for cancer is undisputed; strong preclinical evidence has resulted in the approval of several new agents for cancer treatment. The type I insulin-like growth factor receptor (IGF1R) appeared to be one of these promising new targets. Substantial population and preclinical data have all pointed toward this pathway as an important regulator of tumor cell biology. Although early results from clinical trials that targeted the IGF1R showed some evidence of response, larger randomized phase III trials have not shown clear clinical benefit of targeting this pathway in combination with conventional strategies. These disappointing results have resulted in the discontinuation of several anti-IGF1R programs. However, the conduct of these trials has brought to the forefront several important factors that need to be considered in the conduct of future clinical trials. The need to develop biomarkers, a clearer understanding of insulin receptor function, and defining rational combination regimens all require further consideration. In this commentary, the current state of IGF1R inhibitors in cancer therapy is reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naing, A., LoRusso, P., Fu, S., Hong, D. S., Anderson, P., Benjamin, R. S., Ludwig, J., Chen, H. X., Doyle, L. A., & Kurzrock, R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0061 · Cited by 205 · cited 1×
“Early reports suggest that this combination of IGF1R and mTOR inhibition has clinical benefits in Ewing’s sarcoma (53).”
BackgroundHaluska, P., Worden, F., Olmos, D., Yin, D., Schteingart, D., Batzel, G. N., Paccagnella, M. L., de Bono, J. S., Gualberto, A., & Hammer, G. D. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1083-9 · Cited by 197
Cited by
Nedeljković, M., & Damjanović, A. (2019) · Cells · doi:10.3390/cells8090957 · Cited by 870
Obesity and diabetes: the increased risk of cancer and cancer-related mortality
Gallagher, E. J., & LeRoith, D. (2015) · Physiological Reviews · doi:10.1152/physrev.00030.2014 · Cited by 806
Finlay, M. R. V., Anderton, M., Ashton, S., Ballard, P., Bethel, P. A., Box, M. R., Bradbury, R. H., Brown, S. J., Butterworth, S., Campbell, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500973a · Cited by 636
Insulin-like growth factors: Ligands, binding proteins, and receptors
LeRoith, D., Holly, J. M. P., & Forbes, B. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101245 · Cited by 303
Insulin-Like Growth Factor System in Cancer: Novel Targeted Therapies
Brahmkhatri, V. P., Prasanna, C., & Atreya, H. S. (2015) · BioMed Research International · doi:10.1155/2015/538019 · Cited by 279
Metadata
- Authors
- Yee, D.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-07-03
- Volume
- 104
- Issue
- 13
- Pages
- 975-981
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2131058993
- Cited by
- 177
- References
- 2
- FWCI
- 21.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insulin-like Growth Factor Receptor Inhibitors: Baby or the Bathwater? https://app.cochat.ai/papers/10.1093/jnci/djs258
- The paper
- Yee, D. (2012). Insulin-like Growth Factor Receptor Inhibitors: Baby or the Bathwater? JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djs258
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.